Key facts
- Notable investors include QAI Ventures, Imbolc Partners.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Qnity (Biotechnology)
- ·The full record, as it builds
Funding rounds
No funding rounds for Qnity (Biotechnology) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Qnity (Biotechnology)
Operator of a molecular screening technology company intended to revolutionize drug discovery by providing real-time, ultra-sensitive molecular data across all molecule sizes. The company offers a quantum-electrochemical device capable of sensitive binding affinity screening at attomolar concentrations, enabling customers to analyze small molecules and complex biologics in real time with throughput capability.
- Sector
- Healthcare
- HQ
- Sao Paulo, Brazil
- Founded
- 2022
- Employees
- 7
- Website
- qnity.bio/
- Ownership
- Privately Held (backing)
Qnity (Biotechnology) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Qnity (Biotechnology) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Qnity (Biotechnology) in its N-PORT filings yet. We sweep new filings monthly.